Immunotherapy for Metastatic Kidney Cancer Shows Increased Survival
2 Visualizzazioni
• 07/10/23
0
0
Incorporare
administrator
Iscritti
The immune checkpoint inhibitor Opdivo (nivolumab) has been shown to increase survival for patients with metastatic clear cell kidney cancer (also called renal cell carcinoma, or RCC).
Mostra di più
Commenti su Facebook
SORT BY-
I migliori commenti
-
Ultimi commenti